

~~73~~² (amended). The method according to claim ~~68~~¹ or ~~69~~² in which the malignancy is colon cancer.

~~74~~² (amended). The method according to claim ~~68~~¹ or ~~69~~² in which the malignancy is selected from the group consisting of melanoma, seminoma, and lung cancer.

~~75~~² (amended). The method according to claim ~~68~~¹ or ~~69~~² in which the level of expression of the Notch protein or ^{molecule} ~~derivative~~ is measured by a method comprising contacting the sample with an anti-Notch antibody such that immunospecific binding can occur, and measuring the amount of any immunospecific binding of the antibody that occurs.

Please add the following new claims:

90 (new). The method according to claim 68 or 69 in which the level of expression of the Notch protein or derivative is measured by a method comprising contacting the sample with a nucleic acid probe capable of hybridizing to Notch RNA, under conditions such that hybridization can occur, and measuring the amount of any hybridization that occurs between the probe and nucleic acids in the sample.

91 (new). A method of screening for the presence of a disease or disorder of the nervous system characterized by an aberrant level of a Notch protein or Notch derivative in a patient, comprising measuring the level of expression of a Notch protein or of a Notch derivative capable of being bound by an anti-Notch antibody in a sample derived from the patient, in which an increase or decrease in the Notch protein or derivative in the patient sample relative to the level found in such a sample from an individual not having the disease or disorder indicates the presence of the disease or disorder in the patient.